Chemotherapy of advanced non small cell lung cancer: Effect on survival and symptoms affecting quality of life;Ocena wpływu chemioterapii na czas przeżycia i wybrane objawy wpływaja̧ce na jakość życia chorych na niedrobnokomórkowego raka płuca w HIB i IV stopniu zaawansowania

Pneumonologia i Alergologia Polska

Volumn 75, Issue 4, 2007, Pages 343-348

  Rolski, Janusz ^a   Zemełka, Tomasz ^a   Jasiówka, Marek ^a   Czyzewicz, Grzegorz ^a   Kojs Pasinæska, Ewelina ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Chemotherapy; Non small cell lung cancer; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; MITOMYCIN; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; POLAND; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING; POLAND; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 38149100418     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Wojciechowska U., Didkowska J., Zatoński W. Nowotwory złośliwe w Polsce w 2003 r, Centrum Onkologii - Instytut im, M. Skłodowskiej-Curie. Warszawa, 2005.
2. Weick J.K., Crowley J., Natale R.B. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Group study. J, Clin. Oncol. 1991: 9: 1157-1162.
3. Elis P.A., Smith I.E., Nicolson M.C. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br. J. Cancer 1995: 71: 366-370.
4. Depierre A., Chastang C., Quoix E. i wsp. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial, Ann. Oncol. 1994: 5: 37-42.
5. Sandler A.B., Neumanaitis J., Denham C. i wsp. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small lung cancer. J. Clin. Oncol. 2000; 18: 122-130.
6. Spiro S.G., Rudd R.M., Souhami R.L. i wsp. Chemotherapy versus supportive care in advanced non small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59: B28-836.
7. Bunn P.A. The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin. Oncol. 1989; 16: 10-21.
8. Haura E.B. Management of advanced non-small cell lung cancer: current trends. Curr. Opin. Pulm. Med. 2002; 8: 251-256.
9. Non-small cell lung cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
10. Schiller J.H., Harrington D., Belani P. i wsp. Comparison of four chemotheraphy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002; 346: 92-98.
11. Scagliotti G.V., Marinis F., Rinaldi M. i wsp. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 2002; 20: 4285-4291.
12. Le Chevalier T., Brisgand D., Douillard J. i wsp. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone, in advanced non-small-cell lung cancer: results of European multicenter trial including 612 patients. J. Clin. Oncol. 1994; 12: 360-367.
13. Bonomi P., Kim K., Chang A. i wsp. Phase III trial comparing etoposide (E). cisplatin (C). versus Taxol (T) with cisplatin G-CSF (G) versus Taxol-cisplatin in advanced non-small-cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc. Am. Soc. Clin. Oncol. 1996; 15: 382a.
14. Giaccone G., Splinter T.A., Debruyne C. i wsp. Randomized study of paclitaxel-cisplatin versus cisplatin-taniposide in patients with advanced non-small-cell lung cancer, The European Organisation for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. 1998; 16: 2133-2141.
15. Belani C., Natale R., Lee J. i wsp. Randomized phase III trial comparing clsplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 1998; 455a.
16. Crino L., Mosconi A.M., Scagliotti G.V. i wsp. Gemcytabine as second-line treatment for relapsing or refractory advanced non-small-cell lung cancer: a phase II trial. Semin. Oncol. 1998; 25: 23-26.
17. Cardenal F., Lopez-Cabrerizo M.P., Anton A. i wsp. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 1999; 17: 12-18.
18. Cullen M.H., Billingham L.J., Woodrffe C.M. i wsp. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effect on survival and quality of life. J. Clin. Oncol. 1999; 17: 3138-3194.